CY1113711T1 - Ρυθμιστικα στοιχεια νουκλεϊκου οξεος - Google Patents
Ρυθμιστικα στοιχεια νουκλεϊκου οξεοςInfo
- Publication number
- CY1113711T1 CY1113711T1 CY20131100160T CY131100160T CY1113711T1 CY 1113711 T1 CY1113711 T1 CY 1113711T1 CY 20131100160 T CY20131100160 T CY 20131100160T CY 131100160 T CY131100160 T CY 131100160T CY 1113711 T1 CY1113711 T1 CY 1113711T1
- Authority
- CY
- Cyprus
- Prior art keywords
- expression
- sequence
- elements
- genome
- position effects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά αλληλουχίες DNA, ιδιαιτέρως στοιχεία που αυξάνουν τη μεταγραφή ή την έκφραση (ΤΕ-στοιχεία), καθώς και τη χρήση τους σε έναν φορέα έκφρασης σε σύνδεση με έναν ενισχυτή, έναν υποκινητή, ένα γονίδιο προϊόντος και έναν δείκτη επιλογής. Η εφεύρεση περιγράφει την αλληλουχία Nr. 1, καθώς και τα ΤΕ-στοιχεία ΤΕ-01, -02, -03, -04, -06, -07, -08, -10, -11 ή -12. Λόγω του μικρού μεγέθους τους είναι προτιμώμενα τα ΤΕ-06, ΤΕ-07 ή ΤΕ-08. Η αλληλουχία Nr. 1 προέρχεται από μια περιοχή αλληλουχίας, η οποία βρίσκεται ανοδικά από την κωδικοποιούσα περιοχή του γονιδίου Ub/S27a από κύτταρα CHO. Τα ΤΕ-στοιχεία προκαλούν αύξηση της έκφρασης του γονιδίου προϊόντος με σταθερή ενσωμάτωση στο ευκαρυωτικό γονιδίωμα, κατά προτίμηση το γονιδίωμα CHO-DG44. Έτσι, υπερνικώνται, ή εξαλείφονται χρωμοσωμικές επιδράσεις θέσης ή υπάρχει προστασία από χρωμοσωμικές επιδράσεις θέσης. Έτσι, τόσο το ποσοστό σε κύτταρα υψηλής παραγωγικότητας ενός μείγματος επιμόλυνσης όσο και το απόλυτο επίπεδο έκφρασης αυξάνονται έως δεκαπέντε φορές.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06117862 | 2006-07-26 | ||
EP07730192A EP2049671B1 (de) | 2006-07-26 | 2007-06-15 | Regulatorische nukleinsäureelemente |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113711T1 true CY1113711T1 (el) | 2016-06-22 |
Family
ID=37441548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100160T CY1113711T1 (el) | 2006-07-26 | 2013-02-21 | Ρυθμιστικα στοιχεια νουκλεϊκου οξεος |
Country Status (23)
Country | Link |
---|---|
US (3) | US20080124760A1 (el) |
EP (1) | EP2049671B1 (el) |
JP (1) | JP5270544B2 (el) |
KR (1) | KR101485853B1 (el) |
CN (1) | CN101517085B (el) |
AR (1) | AR061472A1 (el) |
AU (1) | AU2007278368B2 (el) |
BR (1) | BRPI0714594A2 (el) |
CA (1) | CA2658595C (el) |
CY (1) | CY1113711T1 (el) |
DK (1) | DK2049671T3 (el) |
EA (1) | EA016880B1 (el) |
ES (1) | ES2401654T3 (el) |
HK (1) | HK1134107A1 (el) |
IL (1) | IL196676A0 (el) |
MX (1) | MX2009000781A (el) |
NO (1) | NO20090057L (el) |
NZ (1) | NZ575115A (el) |
PL (1) | PL2049671T3 (el) |
PT (1) | PT2049671E (el) |
SI (1) | SI2049671T1 (el) |
TW (1) | TW200815591A (el) |
WO (1) | WO2008012142A1 (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
KR101993938B1 (ko) | 2011-04-13 | 2019-06-27 | 내셔날 리서치 카운실 오브 캐나다 | IFNα2로부터의 SAR 인자를 갖는 발현 시스템 |
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
JP2017501848A (ja) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
JP6728053B2 (ja) | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗mcam抗体及び関連する使用方法 |
JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI711631B (zh) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
RS61924B1 (sr) * | 2015-02-02 | 2021-06-30 | Meiragtx Uk Ii Ltd | Regulacija genske ekspresije putem aptamerom posredovane modulacije alternativnog splajsovanja |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
JP7076711B2 (ja) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
EP3478715A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3076313A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
CA3117816A1 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
JP7412860B2 (ja) | 2020-10-16 | 2024-01-15 | 株式会社奥村組 | 泥水式シールド掘進機および泥水式シールド掘進機における圧縮空気の圧力調整方法 |
AU2022261882A1 (en) * | 2021-04-21 | 2023-12-07 | Janssen Biotech, Inc. | Materials and methods for improved phosphotransferases |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
US5786166A (en) | 1991-10-25 | 1998-07-28 | University Of Tennessee Research Corporation | Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
DK0873405T3 (da) * | 1996-01-11 | 2005-01-17 | Immunex Corp | Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer |
WO2000034319A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034326A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034325A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
ES2257303T3 (es) | 1999-07-12 | 2006-08-01 | Genentech, Inc. | Vectores de expresion y procedimientos. |
EP1305412A2 (en) | 1999-10-14 | 2003-05-02 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
DE60235616D1 (de) | 2001-04-05 | 2010-04-22 | Millipore Corp | Gesteigerte genexpression |
PT1600510E (pt) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | Sequências de adn com actividade anti-repressora. |
US7344886B2 (en) * | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
DK1567652T3 (da) | 2002-11-29 | 2007-11-26 | Boehringer Ingelheim Pharma | Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler |
DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
-
2007
- 2007-06-13 US US11/762,240 patent/US20080124760A1/en not_active Abandoned
- 2007-06-14 TW TW096121483A patent/TW200815591A/zh unknown
- 2007-06-15 NZ NZ575115A patent/NZ575115A/en not_active IP Right Cessation
- 2007-06-15 AU AU2007278368A patent/AU2007278368B2/en active Active
- 2007-06-15 JP JP2009521178A patent/JP5270544B2/ja active Active
- 2007-06-15 DK DK07730192.7T patent/DK2049671T3/da active
- 2007-06-15 CN CN2007800359296A patent/CN101517085B/zh active Active
- 2007-06-15 EP EP07730192A patent/EP2049671B1/de active Active
- 2007-06-15 WO PCT/EP2007/055954 patent/WO2008012142A1/de active Application Filing
- 2007-06-15 AR ARP070102632A patent/AR061472A1/es active Pending
- 2007-06-15 PT PT77301927T patent/PT2049671E/pt unknown
- 2007-06-15 CA CA2658595A patent/CA2658595C/en active Active
- 2007-06-15 PL PL07730192T patent/PL2049671T3/pl unknown
- 2007-06-15 EA EA200900212A patent/EA016880B1/ru not_active IP Right Cessation
- 2007-06-15 KR KR1020097004079A patent/KR101485853B1/ko active IP Right Grant
- 2007-06-15 ES ES07730192T patent/ES2401654T3/es active Active
- 2007-06-15 SI SI200731174T patent/SI2049671T1/sl unknown
- 2007-06-15 BR BRPI0714594-2A patent/BRPI0714594A2/pt not_active IP Right Cessation
- 2007-06-15 MX MX2009000781A patent/MX2009000781A/es active IP Right Grant
-
2009
- 2009-01-06 NO NO20090057A patent/NO20090057L/no not_active Application Discontinuation
- 2009-01-22 IL IL196676A patent/IL196676A0/en unknown
-
2010
- 2010-01-28 HK HK10100907.0A patent/HK1134107A1/xx not_active IP Right Cessation
- 2010-07-23 US US12/842,468 patent/US9045776B2/en active Active
-
2013
- 2013-02-21 CY CY20131100160T patent/CY1113711T1/el unknown
-
2015
- 2015-04-29 US US14/699,182 patent/US9708626B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR061472A1 (es) | 2008-08-27 |
HK1134107A1 (en) | 2010-04-16 |
AU2007278368A1 (en) | 2008-01-31 |
ES2401654T3 (es) | 2013-04-23 |
JP5270544B2 (ja) | 2013-08-21 |
CN101517085B (zh) | 2013-08-07 |
SI2049671T1 (sl) | 2013-04-30 |
PT2049671E (pt) | 2013-01-24 |
US9045776B2 (en) | 2015-06-02 |
EA200900212A1 (ru) | 2009-10-30 |
US20150337333A1 (en) | 2015-11-26 |
JP2009544293A (ja) | 2009-12-17 |
EP2049671B1 (de) | 2012-12-19 |
KR101485853B1 (ko) | 2015-01-23 |
IL196676A0 (en) | 2011-08-01 |
TW200815591A (en) | 2008-04-01 |
CA2658595C (en) | 2016-05-31 |
EP2049671A1 (de) | 2009-04-22 |
KR20090046887A (ko) | 2009-05-11 |
CN101517085A (zh) | 2009-08-26 |
WO2008012142A1 (de) | 2008-01-31 |
EA016880B1 (ru) | 2012-08-30 |
CA2658595A1 (en) | 2008-01-31 |
US20100311121A1 (en) | 2010-12-09 |
BRPI0714594A2 (pt) | 2013-02-19 |
US20080124760A1 (en) | 2008-05-29 |
US9708626B2 (en) | 2017-07-18 |
AU2007278368B2 (en) | 2013-12-19 |
NO20090057L (no) | 2009-02-16 |
PL2049671T3 (pl) | 2013-05-31 |
MX2009000781A (es) | 2009-01-29 |
NZ575115A (en) | 2011-10-28 |
DK2049671T3 (da) | 2013-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113711T1 (el) | Ρυθμιστικα στοιχεια νουκλεϊκου οξεος | |
HRP20210449T1 (hr) | 3' utr sekvence za stabilizaciju rnk | |
WO2022067130A3 (en) | Prime editing guide rnas, compositions thereof, and methods of using the same | |
CY1121457T1 (el) | Πολυλειτουργικα αλληλομορφα | |
ES2660459T3 (es) | Moléculas de ácido nucleico artificiales | |
ES2601200T3 (es) | Método para producir un compuesto de interés en una célula fúngica filamentosa | |
CY1120265T1 (el) | Μεθοδος παραγωγης αντισωματος με μεταβλητη περιοχη ανθρωπου και με σταθερη περιοχη τρωκτικου | |
CY1121599T1 (el) | Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα | |
AR097495A1 (es) | Constructos para expresar transgenes con el uso de elementos reguladores provenientes de genes ubiquitina 1c de brachypodium | |
EA201201264A1 (ru) | Молекулы полинуклеотидов для регуляции генов у растений | |
CY1116417T1 (el) | Καλλιεργειες με βελτιωμενη αντοχη σε φαγους | |
Welden et al. | Pre-mRNA structures forming circular RNAs | |
DK1412493T3 (da) | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer | |
AR057044A1 (es) | Composiciones con modificadores de reologia hase | |
RU2018123181A (ru) | Synp161, промотор для специфической экспрессии генов в палочковых фоторецепторах | |
DK1266011T3 (da) | Svampetranskriptionsaktivator, der er anvendelig i fremgangsmåder til fremstilling af polypeptider | |
AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
CA2678055C (en) | Rna interference tags | |
RU2014132889A (ru) | Микроорганизм из рода escherichia, обладающий усиленной способностью к продукции l-триптофана, и способ получения l-триптофана с его использованием | |
MX2012000972A (es) | Secuencias de centromeros y mini cromosomas de caña de azucar. | |
ES2548990T3 (es) | Método para la producción de partículas de vector poliomavírico recombinante | |
Schor et al. | Intragenic chromatin modifications: a new layer in alternative splicing regulation | |
WO2006085942A3 (en) | Compositions and methods for regulating gene transcription | |
CO5670372A2 (es) | Vacuna derivadas de mucina de celula epitelial muc-1 | |
Liu et al. | An unusual intragenic promoter of PIWIL2 contributes to aberrant activation of oncogenic PL2L60 |